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Phenotypic Characterization, Osteoblastic Differentiation, and 
Bone Regeneration Capacity of Human Embryonic 
Stem Cell–Derived Mesenchymal Stem Cells
Premjit Arpornmaeklong, Shelley E. Brown, Zhuo Wang, and Paul H. Krebsbach
To enhance the understanding of differentiation patterns and bone formation capacity of hESCs, we determined 
(1) the temporal pattern of osteoblastic differentiation of human embryonic stem cell–derived mesenchymal 
stem cells (hESC-MSCs), (2) the infl uence of a three-dimensional matrix on the osteogenic differentiation of 
hESC-MSCs in long-term culture, and (3) the bone-forming capacity of osteoblast-like cells derived from hESC-
MSCs in calvarial defects. Incubation of hESC-MSCs in osteogenic medium induced osteoblastic differentiation 
of hESC-MSCs into mature osteoblasts in a similar chronological pattern to human bone marrow stromal cells 
and primary osteoblasts. Osteogenic differentiation was enhanced by culturing the cells on three-dimensional 
collagen scaffolds. Fluorescent-activated cell sorting of alkaline phosphatase expressing cells was used to obtain 
an enriched osteogenic cell population for in vivo transplantation. The identifi cation of green fl uorescence pro-
tein and expression of human-specifi c nuclear antigen in osteocytes in newly formed bone verifi ed the role of 
transplanted human cells in the bone regeneration process. The current cell culture model and osteogenic cell 
enrichment method could provide large numbers of osteoprogenitor cells for analysis of differentiation patterns 
and cell transplantation to regenerate skeletal defects.
Introduction
The transplantation of stem or progenitor cells may soon be an optional treatment for the repair of skeletal 
defects, particularly in wound beds with low numbers of 
osteoprogenitor cells or poor vascularization such as in irra-
diated or scared tissue sites. Such transplantation procedures 
would require adequate numbers of cells with a well-defi ned 
differentiation pattern and ease of procurement for bone re-
generation [1,2]. Some of these challenges of cell transplanta-
tion may be met by the use of human embryonic stem cells 
(hESCs) that have the potential to differentiate into multiple 
cell types with relative ease of accessibility. By controlling 
cell culture conditions, differentiation of hESCs may be di-
rected and restricted to desired cell lineages in potentially 
unlimited numbers [3,4].
Any potential use of hESCs for skeletal regeneration 
would require a reproducible method to ensure osteoblast 
differentiation and function. To reach this goal, a number 
of cell culture conditions have been used to induce differ-
entiation of hESCs through the osteoblastic lineage with 
and without embryonic body formation [5–12]. Osteoblastic 
differentiation of hESCs has been achieved by introducing 
hESCs or hESC-derived mesenchymal stem cells (hESC-
MSCs) in osteogenic medium supplemented with dexameth-
asone and ascorbic acid [5–12] or co-cultured with human 
primary bone-derived cells without the use of exogenous 
factors [13].
Differentiating hESCs into MSCs before undergoing 
lineage-specifi c differentiation provides the advantage of 
producing a large source of multipotent progenitor cells 
that can be expanded and differentiated into specifi ed lin-
eages such as bone, cartilage, or fat [4,14]. To date, the dif-
ferentiation conditions for deriving MSCs from hESCs have 
required long culture periods [5], were dependent on a 
feeder layer, and demonstrated low yields of MSCs [10,15]. 
Generating MSCs in serum-free conditions supplemented 
with PDGF AB and FGF2 has also been reported [16]. To 
satisfy the likely demand for high numbers of progenitor 
cells to regenerate skeletal defects via a tissue engineer-
ing approach, cell culture conditions must be improved to 
assure appropriate and consistent differentiation of hESCs 
into MSCs on a large scale.
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Mesenchymal stem cell phenotypic characterization
Characterization and comparison of the MSC pheno-
types of hESC-MSCs and human bone marrow stromal cells 
(hBMSCs) in MSC medium were performed by examin-
ing expression of MSC cell surface antigens and perform-
ing functional differentiation analyses. Expression of MSC 
surface markers was analyzed by fl ow cytometric methods. 
Immunohistochemical staining was performed to identify 
expression of cell surface markers in mesodermal, ectoder-
mal, and endodermal lineages. For functional differentiation, 
hESC-MSCs at passages 6–7 were induced to differentiate 
into adipogenic, chondrogenic, and osteogenic lineages in 
cell-specifi c culture medium.
Flow cytometric analysis of cell surface antigens
Expression of the cell surface antigen profi le of MSCs 
was characterized using fl uorescent-activated cell sorting 
(FACS). Human ES-MSCs were harvested using 0.25% colla-
genase in DPBS and trypsin 0.25% EDTA. After neutraliza-
tion, single cell suspensions were washed in cold BSA (0.5% 
w:v) (Sigma) in DPBS and incubated at a concentration of 
1 × 106 cells/mL in 1 μg/mL unconjugated goat anti-human 
IgG (Caltag/Invitrogen) on ice for 15 min to block nonspe-
cifi c binding. Samples (2.5 × 105 cells) were then incubated 
on ice with the optimal dilution of conjugated monoclonal 
antibody (mAb) in 1 μg/mL unconjugate goat anti-human 
IgG in the dark. All mAbs were of the immunoglobulin G1 
(IgG1) isotype. The following conjugated antibodies were 
used in the analyses: allophycocyanin (APC)-conjugated 
antibodies against CD44 (BD PharmingenTM, San Jose, CA) 
and alkaline phosphatase (R&D system, Minneapolis, MN). 
Fluorescein isothiocyanate (FITC)-conjugated mAbs against 
CD29, CD90, and CD45 (all from BD). Phycoerythrin (PE)-
conjugated mAbs against CD49a, CD49e, CD73, and CD166 
(all from BD), CD105 (eBioscience, San Diego, CA), and 
STRO-1 (Santa Cruz Biotechnology, Santa Cruz, CA). After 30 
min incubation, cells were washed twice with ice cold 0.5% 
BSA in DPBS. Nonspecifi c fl uorescence was determined by 
incubating cells with conjugated mAbs raised against anti-
human IgG1 (all from BD).
At least 10,000 events were acquired for each sam-
ple using a fl uorescent-activated cell sorting instrument 
(FACSCalibur; Becton Dickinson, San Jose, CA) and cell 
fl ow cytometry data were analyzed using CELLQUEST soft-
ware (Becton Dickinson). The fl uorescence histogram for 
each mAb was displayed alongside the control antibody. 
Percentages of positive cells were subtracted from the iso-
type control antibody of each conjugate. Single cell suspen-
sions from two hESC-MSCs differentiated cell strains and 
one hBMSCs donor were analyzed.
Induction of adipogenic differentiation
Culturing hESC-MSCs in adipogenic medium at 1 × 104 
cells/cm2 for 14 days induced adipogenic differentiation. 
Adipogenic medium was changed every 3 days and was 
comprised of 90% DMEM high glucose (Gibco), 10% heat-
inactivated FBS (Gibco), 1 μM dexamethasone, 10 μg/mL 
insulin, 0.5 mM 3-isobutyl-1-methylxanthine, and 0.2 mM 
indomethacin (all from Sigma) [5]. Expression of adipo-
genic differentiation was determined by Oil Red O staining 
The present study describes a cell culture method and 
osteogenic cell enrichment strategy that could provide 
large numbers of osteoprogenitor cells for analysis and cell 
transplantation. The progressive patterns of osteogenic dif-
ferentiation and effects of three-dimensional matrix on oste-
ogenic differentiation of hESC-MSCs in long-term culture 
suggest that the hESC-derived MSCs may be a good source 
of cells for skeletal regeneration.
Materials and Methods
Human embryonic stem cell culture
Human embryonic stem cells (hESCs) (BG01; Bresagen, 
Inc., Atlanta, GA) were cultured on irradiated mouse embry-
onic fi broblast (MEF) feeder layers following the protocol of 
the University of Michigan Stem Cell Core. Human ESCs were 
maintained in serum-free growth medium comprised of 80% 
DMEM-F12 supplemented with 20% (v/v) knockout serum 
replacement (KOSR), 200 mM l-glutamine, 10 mM nonessen-
tial amino acids (all from Gibco/Invitrogen, Carlbad, CA), 
14.3 M β-mercaptoethanol (Sigma, St. Louis, MO), and 4 ng/
mL β-FGF (Invitrogen). Cell cultures were incubated at 37°C 
in 5% CO2 at 95% humidity and manually passaged every 
7 days. Culture medium was changed every day.
Induction of mesenchymal stem cell differentiation
Aggregates of undifferentiated hESCs were cultured in 
mesenchymal stem cell culture medium (MSC medium) 
consisting of 80% α-minimum essential medium (α-MEM), 
10% heat-inactivated fetal bovine serum (FBS), 200 mM 
l-glutamine, and 10 mM nonessential amino acids (all from 
Gibco) to induce mesenchymal differentiation of the undif-
ferentiated cells [5]. Culture medium was changed every 
3 days. Undifferentiated hESCs were manually harvested 
as cell aggregates and were seeded on fi bronectin (Gibco)-
coated plates (Corning Life Sciences, Lowell, MA) (20 μg/
mL, 2 mL/60 mm plate) in a ratio of one to one. Cell adhe-
sion and proliferation on the matrix were monitored under 
an inverted light microscope. When cells reached confl uence 
(culture-day 14), cells were subcultured at a ratio of 1:2 on 
polystyrene-surfaced culture fl asks (BD Falcon, Bedford, 
MA) using trypsin and ethylenediaminetetraacetic acid 
(0.25% trypsin/EDTA) (Gibco). Cells were then regularly pas-
saged at confl uence (7–10 days) at a ratio of 1:3. Differentiated 
cells derived from these culture conditions at passages 6–7 
were designated hESC-MSCs and used in the analysis for 
MSC phenotypic characterization and differentiation poten-
tial. A karyotype analysis was performed by cytogenetic 
analysis on 20 G-banded metaphase cells of hESC-MSCs at 
passage 8 (Cell Line Genetics, Madison, WI).
Human bone marrow stromal cell culture
Human bone marrow was collected from patients 
undergoing iliac bone graft procedures with University of 
Michigan IRB approval and informed patient consent, and 
bone marrow stromal cells (BMSCs) were isolated and cul-
tured as previously described [17]. Human BMSCs at passage 
4 served as controls and were subjected to cell surface analy-
sis for expressions of MSC surface antigens and induced to 
differentiate in osteogenic medium.
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Differentiated hESC-MSCs (1 × 105 cells/30 μL) in oste-
ogenic medium (OS4) were trypsinized and suspended in 
20 mg/mL human fi brinogen (Sigma) in a 1.5 mL tube. Five 
microliters of human thrombin (100 unit/mL) (Sigma) was 
added to the fi brinogen-cell suspensions and then directly 
seeded on the collagen scaffold. Cell–fi brin gel and colla-
gen scaffold constructs were maintained in culture medium 
(0.5 mL/60 mm plate) in a humidifi ed incubator at 37°C with 
5% CO2 for 2 h and then 10 mL of osteogenic medium was 
added into each plate. The constructs were cultured in osteo-
genic medium for 28 days and culture medium was replaced 
every 3 days. Levels of ALP activity, osteocalcin secretion, 
and calcium content were monitored on culture-days 7, 14, 
and 28 (n = 4).
Characterization of osteoblastic phenotypes
A leukocyte alkaline phosphatase kit (Sigma-Aldrich 
Chemie, Steinheim, Germany) was used for ALP staining 
following the recommended protocol. Cells were counter-
stained with 0.05% neutral red (Sigma). For alizarin red 
staining, cells were fi xed in Z-FIX aqueous buffered zinc for-
malin (Anatech, Battle Creek, MI) for 4 min and stained for 
10 min with 1 mL of 40 mM Alizarin red (Sigma) following 
the standard protocol [18]. For von Kossa staining of miner-
alized matrix on the collagen scaffolds, after deparaffi niza-
tion, slides were immersed in 2% silver nitrate (Sigma) with 
exposure to a 60-W lamp for 1 h, subsequently treated in 
2% sodium thiosulfate (Sigma) for 5 min and counterstained 
with a 5% nuclear fast red solution following standard pro-
tocols [20].
Protein analysis, ALP activity, osteocalcin secretion, and 
calcium content were measured. For ALP activity and pro-
tein content analyses, cells were washed with DPBS and 
stored at −20°C prior to the analysis. For osteocalcin analy-
sis, cells were washed with DPBS and incubated in serum-
free culture medium (1 mL/one six-well plate) for 12 h, then 
the culture medium was collected and stored at −70°C for 
the analysis and cells were washed with DPBS and stored 
at −20°C for measurement of ALP activity and calcium and 
protein contents.
Cell lysis and cellular protein analysis
At each experimental end point, cells in six-well plates 
and the scaffolds were washed two times in DPBS (Gibco). 
Cells were lysed by incubation in 1% Triton X-100 (Sigma) 
in DPBS on ice for 1.5 h. Protein solutions were centrifuged 
at 2,000g for 15 min at 4°C. The supernatants were stored at 
−20°C for the analysis of ALP activity and protein content 
and cell pellets were stored for calcium content analysis.
The quantifi cation of protein in cell lysates was performed 
according to the manufacturer’s instruction (Bio-Rad Protein 
assay kit; BIO-RAD, Hercules, CA). The solutions were read 
at 650 nm (A650) in duplicate using a microplate reader 
(Biotek-μQuant; Bio-Tek Instruments Inc., Winooski, VT). 
Total cellular protein was determined on the same samples 
as the ALP activity and osteocalcin measurements [21].
Alkaline phosphatase assay
The cell protein solutions were assayed for ALP activ-
ity using Alkaline Phosphatase Yellow Liquid Substrate 
on culture-day 14 using standard techniques as previously 
described [18].
Induction of chondrogenic differentiation
Chondrogenic differentiation was induced by culturing 
cell pellets in chondrogenic medium. For cell pellet cultures, 
2 × 106 hESC-MSCs were suspended in 2 mL of chondro-
genic medium in 15 mL centrifugation tubes and centrifuged 
at 600g for 5 min and cultured in chondrogenic medium 
for 21 days. Culture medium was changed every 3 days. 
Chondrogenic medium consisted of high glucose DMEM 
(Gibco) supplemented with 10% FBS (Gibco), 100 mM sodium 
pyruvate, 40 μg/mL proline, 100 nM  dexamethasone, 200 μM 
ascorbic acid (all from Sigma), and 10 ng/mL TGF-β3 (R&D 
systems). Determination of expression of chondrogenic dif-
ferentiation was performed after 21 days of culture using saf-
ranin O staining and immunohistochemical  identifi cation of 
collagen type II following standard  techniques [19].
Induction of osteogenic differentiation
Human ESC-MSCs were cultured in osteogenic medium at 
5 × 103 cells/cm2 to induce osteogenic differentiation. The dif-
ferentiated cells were continually passaged every 4–5 days as 
cells approached about 80% confl uence. Osteogenic medium 
was comprised of 90% α-MEM (Gibco), 10% heat-inactivated 
FBS (Gibco), 50 μg/mL ascorbic acid, 5 mM β-glycerophosphate, 
and 100 nM dexamethasone (all from Sigma) [9]. Culture 
medium was changed every 3 days. Monitoring of osteogenic 
differentiation was performed when cells were fi rst exposed 
to osteogenic medium (OS1) and when cells were passaged 
four times in osteogenic medium (OS4). The differentiated 
cells passaged in the osteogenic medium for the fourth time 
(hESC-MSCs-OS) were used in the analyses.
Osteogenic differentiation on two- and 
three-dimensional matrices
For two-dimensional cell cultures, hESC-MSCs that were 
serially passaged in osteogenic medium (hESC-MSCs-OS) 
were seeded in six-well plates (Corning Life Science) at 5 
× 104 cells/well. Human ESCs-MSCs in standard culture 
medium with 10% FBS were monitored as negative controls. 
Osteogenic differentiation was characterized by quantify-
ing alkaline phosphatase (ALP) activity, osteocalcin secre-
tion into the culture medium, and levels of calcium content 
in the mineralized extracellular matrix (ECM). Detection of 
ALP activity was performed after 3 days and every 7 days 
thereafter for 28 days. Levels of osteocalcin in the culture 
medium and calcium content were monitored on culture-
days 7, 14, and 28 (n = 4).
Three-dimensional cell culture
For three-dimensional cell cultures, 1 × 105 cells were 
seeded on 5 × 3 mm 3-D collagen composite scaffolds (BD 
Biosciences Discovery Labware, Bedford, MA). Scaffolds 
were neutralized in MSC culture medium over night at 
37°C. Prior to cell seeding, excess fl uid was removed from 
the scaffolds using fi lter paper. Hydrated scaffolds were 
placed individually in 60 mm bacterial cell culture plates 
(BD Falcon, Bedford, MA).
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fi xed in methanol at −20°C for 5 min and washed twice with 
DPBS. For paraffi n-embedded sections, histological sections 
were deparaffi nized and permeabilized with Triton (0.3% 
w:v) (Sigma) in DPBS for 30 min. For the detection of col-
lagen type II expression in cell pellet cultures, following 
deparaffi nization the sections were digested with 1 mg/
mL pepsin from porcine gastric mucosa (Sigma) in Tris-
HCL, pH 2.0 for 15 min at 37°C. In each washing step, cells 
on chamber slides and histological sections were washed in 
0.5% BSA in DPBS.
To detect cell surface antigen expression on cultured 
cells, primary monoclonal and polyclonal antibodies were 
used in the following concentrations: rabbit polyclonal to 
CD105 1:200, mouse monoclonal to CD166 1:200, rabbit poly-
clonal to brachyury/Bry 1:50, mouse monoclonal to Runx2 
1:200, and mouse monoclonal to alpha smooth muscle actin 
1:200 (all from Abcam, Cambridge, MA), mouse monoclo-
nal to vimentin 1:200, mouse monoclonal to collagen type I 
1:200, goat polyclonal to α-fetoprotein 1:200, mouse monoclo-
nal to VCAM-1 1:200, mouse monoclonal to estrogen recep-
tor alpha (ERα) 1:200, and mouse monoclonal to β-catenin 
1:200 (all from Santa Cruz Biotechnology). All immunohis-
tochemical staining of cultured cells was performed at the 
same setting. To determine the expression of collagen type 
II in the ECM of cell pellets, mouse monoclonal antibody to 
collagen II, prediluted (Abcam) was applied.
To identify deposition of bone matrix on collagen scaf-
folds, mouse monoclonal antibodies to ALP 1:500 and rabbit 
monoclonal to osteonectin (Anti-Sprac) 1:200 (all from Sigma 
Life Science, St. Louis, MO), mouse monoclonal to osteopon-
tin 1:200 (Santa Cruz Biotechnology) and mouse monoclonal 
to osteocalcin 1:100 (Abcam) were applied.
To identify the origin of transplanted cells, paraffi n-
embedded sections were stained with chicken polyclonal 
antibodies to green fl uorescent protein (GFP) 1:200 (Abcam) 
and mouse monoclonal to human-specifi c nuclear antigen 
(HuNu) 1:50 (Chemicon/Millipore, Billerica, CA).
Negative controls were performed by omitting the pri-
mary monoclonal antibody. Throughout the study, the R.T.U. 
Vectastain Universal Elite ABC Kit and either Vector AEC, 
DAB or Vector® NovaRedTM (red) substrate kits (Vector lab-
oratories, Burlingame, CA) were used. Except for the detec-
tion of chicken polyclonal to GFP, biotinylated anti-chicken 
IgG (H+L) (Vector laboratories) was used instead of predi-
luted biotinylated horse antibody anti-rabbit and mouse IgG 
(H+L) containing in the ABC kit. Immunohistochemical 
staining was performed according to manufacturer’s in-
struction (Vector laboratories). Gill’s formula hematoxylin 
(Vector laboratories) was used for counterstaining. Cells 
on chamber and histological slides detected with AEC and 
DAB substrates were covered with Crystal Mount Aqueous 
Mounting Medium (Sigma) and for cell pellet sections 
detected with NovaRedTM substrate, VectaMountTM perma-
nent mounting medium was applied. Sections were then an-
alyzed under a light microscope (Nikon Eclipse E600; Nikon, 
Shinakawa-ku, Japan).
Retrovirus-mediated infection of cells
Differentiated hESC-MSCs in osteogenic medium (OS4) 
were plated at a density of 5 × 103 cells/cm2. After 24 h, cells 
were washed twice with DPBS and incubated with recom-
binant lentivirus vector (HIV-GFP) [23] (Vector Core, The 
for ELISA (Sigma) according to the manufacturer’s instruc-
tions. One hundred microliters of protein solution was 
added to 1,000 μL of working solution and incubated for 1 
h at 37°C and subsequently 250 μL of 3 M sodium hydrox-
ide (Sigma) was added to each well to stop the reaction. 
Standards were prepared in concentrations ranging from 0 
to 50 μM of p-nitrophenol (Sigma). The solutions were read 
at A405 nm in triplicate using a microtiter plate reader (Bio-
Tek Instruments Inc., Winooski, VT). The concentration of 
p-nitrophenol in the assay was measured, correlated to stan-
dard concentrations, and normalized to the protein content 
in the cell lysate solutions (μM p-nitrophenol/mg protein). A 
total of fi ve samples of each group were tested at each time 
point [21].
Osteocalcin assay
Quantifi cation of osteocalcin in serum-free cell cul-
ture medium was performed according to the manufac-
turer’s instruction using the Gla-type Osteocalcin EIA kit 
(TAKARA, Shiga, Japan). The solutions were read at A450 nm 
in duplicate using a microplate reader (Bio-Tek Instruments 
Inc., Winooski, VT). A total cellular protein analysis was 
performed on the same samples as the ALP activity and 
calcium content measurements. The assay was performed 
on culture-days 7, 14, and 28. Levels of osteocalcin were 
reported as nanograms per milligram protein (ng/mg pro-
tein). A total of four samples of each group were tested at 
each time point [21].
Analysis of calcium content
The analysis of calcium deposition in the ECM of cells in 
six-well plates and on collagen scaffolds was modifi ed from 
a previous report [22]. Briefl y, the cell pellets and collagen 
scaffolds were washed two times in DPBS. Excess fl uid was 
removed using absorbent fi lter paper and specimens were 
minced into small pieces with scissors and then incubated in 
0.5 M HCl (Sigma) at 37°C for 12 h. The solutions were then 
centrifuged at 13,000g for 5 min and the supernatants were 
collected and maintained at −20°C for the analysis.
Calcium content in the cell lysate was quantifi ed spec-
trophotometrically with cresolphthalein complexone, 
QuantichromTM Calcium Assay Kit (DICA-500) (BioAssay 
Systems, Hayward, CA) according to the manufacturer’s 
instruction. In a 96-well plate, 5 μL of sample and 200 μL 
of working solution were added to each well and incubated 
at RT for 5 min. The absorbance of the samples was read at 
A575 nm using a microplate reader (Bio-Tek Instruments 
Inc., Winooski, VT). The calcium concentration was calcu-
lated from a standard curve generated from a serial dilution 
of a calcium standard solution. Calcium content in the ECM 
was reported as milligrams of calcium per milligram pro-
tein (mg/mg protein). A total of four samples in each group 
were tested at each time point [21].
Immunohistochemical staining
For staining of cell surface antigens, cells were seeded 
at 2.5 × 104 cells/cm2 in Lab Tek Chamber slides (Nunc, 
Rochester, NY) and cultured in medium supplemented with 
FBS (Gibco) or osteogenic medium according to cell types. 
After 2 days in culture, cells were washed with DPBS and 
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Taq DNA polymerase (Invitrogen) following the manufactur-
er’s recommended cycling conditions. PCR products were 
analyzed on ethidium bromide-stained 1% agarose gel elec-
trophoresis. A 100 base pair DNA ladder (Invitrogen) was 
applied to determine size of DNA bands.
Preparation of cell construct for transplantation
The expanded FCM-sorted cells were harvested using 
0.25% collagenase in DPBS and 0.25% trypsin–0.53 mM 
EDTA. Cell pellets were resuspended in 20 mg/mL human 
plasma fi brinogen at a concentration of 3 × 106 cells per 50 
μL in 1.5 mL tube containing 1.0 mg of Bio-Oss particles 
(particle size 0.25–1.0 mm) (Geistlich Pharma AG, Wolhusen, 
Switzerland). Cell suspensions were thoroughly mixed and 
placed in 1.5 mL tubes containing the cells-Bio-Oss suspen-
sion prior to transplantation.
Surgical procedure and cell transplantation in 
craniofacial defect model
All procedures were approved by the University of 
Michigan Committee on the Use and Care of Animals. Nine 
5-week-old female immunocompromised mice (N:NIH-
bg-nu-xid; Harlan Sprague Dawley, Inc., NC) were anesthe-
tized with intraperitoneal injections of ketamine, (Ketaset, 
75 mg/kg, Fort Dodge Animal Health, Fort Dodge, IA) and 
xylazine (Ansed, 10 mg/kg; Lloyd laboratories, Bedford, 
OH). A semilunar scalp incision was made from right to 
left of the post-auricular areas, and a full-thickness fl ap was 
elevated. The periosteum overlying the calvarial bone was 
completely resected. A trephine was used to create a 5-mm 
craniotomy defect centered on the sagittal suture and the 
calvarial disk was removed.
Five microliters of human thrombin, 200 unit/mL (Sigma) 
was added in cell-Bio-Oss particle suspension and imme-
diately placed over the entire area of the cranial defect. 
The defects were covered with a 6 mm diameter collagen 
membrane (Bio-Gide, Geistlich Pharma AG, Wolhusen, 
Switzerland) to ensure full coverage of the defect site and the 
incisions were closed with 4–0 chromic gut suture (Ethicon/
Johonson&Jhonson, NJ). All mice were sacrifi ced 6 weeks 
after the implantation.
Radiographic and histologic analyses
Radiographic analysis was performed immediately after 
the calvariae were harvested (Faxitron X-ray Corporation, 
University of Michigan, MI) in 12 mL of α-MEM without FBS 
containing 2 × 106 transfection units/mL (2.4 × 107 trans-
fection units in 12 mL) and 6 μg/mL polybrene (Sigma) in 
225 cm2 cell culture fl ask (BD Falcon) for 5 h with gentle man-
ual shaking every 30 min. Subsequently, an equal volume of 
osteogenic medium was added and new osteogenic medium 
was replaced on the next day. Expression of GFP was moni-
tored under a fl uorescent microscope (Nikon Eclipse TE300; 
Nikon, Shinakawa-ku, Japan). On culture-day 3, cells were 
harvested for fl ow cytometric cell sorting of ALP expression 
for cell transplantation.
Flow cytometric cell sorting of ALP expressing 
cells for cell transplantation
GFP-transduced hESC-MSCs-OS were harvested using 
0.25% collagenase in DPBS and 0.25% trypsin/EDTA 48 
h after GFP-retroviral infection. Expression of ALP was 
detected using an APC-conjugated murine mAb against ALP 
(R&D system), according to the procedure stated earlier. Cell 
populations were sorted based on the levels of ALP expres-
sion. Sorted cells were seeded at a density of 1 × 104 cells/
cm2 in osteogenic medium. Culture medium was changed 
every 2 days. When the cells reached confl uence (about day 
5), cells were harvested for transplantation and 1 × 106 cells 
were analyzed for expression of pluripotent and osteoblas-
tic genes using reverse transcriptase-polymerase chain reac-
tion (RT-PCR).
Reverse transcriptase-polymerase chain 
reaction (RT-PCR)
RT-PCR was performed to compare expression of regu-
lators of pluripotency (Oct4 and Nanog) and osteoblast-
associated genes in undifferentiated hESCs, differentiated 
hESC-MSCs in osteogenic medium, and enriched ALP 
expressing osteoprogenitor cells for cell transplantation. 
BMSCs in osteogenic medium were tested as a positive con-
trol for expression of osteoblast-associated genes. Total RNA 
extraction was performed using Trizol (Invitrogen) and 1 μg of 
RNA was used for cDNA synthesis (ThermoScriptTM RT-PCR 
System, Invitrogen) according to the manufacturer’s instruc-
tions. Oct4 and Nanog primers used were for pluripotency 
markers, and the primers for Runx2, ALP, type I collagen 
(ColI), and bone sialoprotein (BSP) were used for markers of 
osteoblastic differentiation. β-actin was included as a house-
keeping gene. Forward and reverse primer sequences are 
listed in Table 1. The RT-PCR was performed using Platinum 
Table 1. Reverse Transcriptase-Polymerase Chain Reaction Primer Sequences
Gene of interest Forward primer Reverse primer
cDNA 
(nucleotides)
Oct4 agtgagaggcaacctggaga gccggttacagaaccacact 125
Nanog ttccttcctccatggatctg tctgctggaggctgaggtat 213
Runx2 ttacttacaccccgccagt c tatggagtgctgctggtctg 139
ALP ggacatgcagtacgagctga ccaccaaatgtgaagacgtg 133
Collagen type I ccccagccacaaagatcta ctcgacttggccttcctctt 125
Bone sialoprotein tgaatacgagggggagtacg gatgcaaagccagaatggat 226
β-actin atctggcaccacaccttctacaatgagctgcg cgtcatactcctgcttgctgatccacatctgc 854
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Expression of MSC cell surface markers in 
differentiated hESC-MSCs
Flow cytometric analysis demonstrated that MSC cell 
surface markers were consistently and highly expressed 
in hESCs and hBMSCs in both MSC and osteogenic media 
(Fig. 2). The MSC surface markers CD29, CD44, CD49e, 
CD73, CD90, CD105, and CD166 were expressed to levels 
greater than 95% in both MSC and osteogenic media (Fig. 
2A). Marked differences in levels of expression in osteogenic 
medium were noted for CD49a, ALP, and STRO-1. In osteo-
genic medium, levels of expression of CD49a and ALP were 
increased to levels higher than 90% and 40%, respectively, 
while levels of STRO-1 in hBMSCs decreased to less than 2%, 
but remained stable in hESC-MSCs (Fig. 2B). Expression of 
the hematopoietic markers, CD34 and CD45, were less than 
0.5% in all cell culture methods (Fig. 2C).
Immunohistochemical determination of 
cell surface antigens
Expression of the MSC surface markers, CD105 and CD166, 
on hESC-MSCs and hBMSCs-MSCs was determined by 
immunohistochemical staining (Fig. 3A,B,M,N). Expression 
of the mesodermal marker, brachyury, and markers of cells 
in the mesenchymal lineage such as smooth muscle α-actin, 
collagen type I, and vimentin was also identifi ed (Fig. 3C–F). 
Expression of VCAM-1 and the endodermal differentiation 
marker α-fetoprotein was not observed in any cultured cells 
(Fig. 3G,H). Intense staining of β-catenin and estrogen recep-
tor was observed on both hESC-MSCs and hBMSCs-MSCs 
(Fig. 3I,J,O,P). High expression of Runx2, as demonstrated by 
nuclear staining, was observed in hESC-MSCs in osteogenic 
medium (OS4) (Fig. 3K). No nonspecifi c binding was found 
in the negative control (Fig. 3L).
hESC-MSCs differentiate into three different 
mesenchymal lineages
For adipogenic differentiation, Oil Red O staining demon-
strated abundant deposition of lipids in the cytoplasm of dif-
ferentiated hESC-MSCs (Fig. 4A). In chondrogenic medium, 
pellet cultures of hESC-MSCs demonstrated the morphology 
of chondroblast-like cells, consisting of cells with large nuclei 
in lacunae surrounded by ECM that stained positive for gly-
cosaminoglycans with safranin O (Fig. 4B). Immunostaining 
of collagen type II confi rmed the presence of a cartilaginous 
matrix in the cell pellet cultures (Fig. 4C). Human ESCs-
MSCs exposed to osteogenic medium for the fi rst time (OS1) 
on culture-day 14 were positive for ALP (Fig. 4D) and were 
able to mineralize the ECM (Fig. 4E), and the progression 
of osteogenic differentiation of hESC-MSCs in osteogenic 
medium was confi rmed by increasing levels of ALP activity 
of hESC-MSCs in osteogenic medium (OS1) that reached the 
highest level on day 14 and was signifi cantly higher than the 
levels of hESC-MSCs in MSC medium (P < 0.01) (Fig. 4G).
hESC-MSCs and enriched osteogenic cells cultured 
in osteogenic medium express osteoblastic genes 
but not pluripotent genetic markers
Undifferentiated hESCs differentiated into osteoblastic 
cells by losing their self-renewal capacity and expressing 
Lincolnshire, IL). The calvariae were subsequently fi xed in 
aqueous buffered zinc formalin, Z-FIX (Anatech) and then 
were subsequently decalcifi ed with a 10% EDTA solution 
for 2–3 weeks, dehydrated with a gradient of alcohols, and 
embedded in paraffi n. Coronal sections 5 μm in thickness 
were cut and stained with hematoxylin and eosin and/or 
reacted with mAbs against human-specifi c nuclear antigen 
and GFP.
Statistical analyses
Data were expressed as the mean value ± the standard 
error of the mean (mean ± SEM) and analyzed by one-way 
analysis of variance. Multiple comparisons with Dunnette 
T3 methods were used. The levels of statistical signifi cance 
were set at P < 0.05.
Results
hESC-MSC cell culture
Aggregates of hESCs in MSC medium adhered and pro-
liferated on fi bronectin-coated plates. hESCs differentiated 
into cells with different morphologies in primary culture 
and reached confl uence on day 7. Cells were allowed to 
mature to day 14 before they were passaged at a ratio of 1:3. 
The recovery rate and homogeneity of cell morphology after 
passaging increased with increasing passage number. In 
early passages, small groups of cells with a fi broblast-like 
morphology were observed and became more uniform in 
size and shape at passages 5–6 and higher (Fig. 1A–C). The 
cells could be passaged at least 12–15 times every 5–7 days. 
Because, as will be demonstrated with the results of our 
study, the cells exhibited a MSC-like phenotype, we termed 
the cells hESC-MSCs. The hESC-MSCs were karyotypically 
normal when tested at passage 8. All 20 G-banded meta-
phase cells demonstrated a normal male karyotype (Cell 
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FIG. 1. Phase contrast images demonstrating morpholog-
ical changes in aggregates of human embryonic stem cells 
(hESCs) cultured in medium supplemented with 10% FBS 
(20×): (A) 2 days after initial cell seeding; (B) after the fi rst 
cell passage; (C) after the seventh cell passage; and (D) a nor-
mal karyotype for hESC mesenchymal stem cells eight pas-
sages after derivation.
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of hBMSCs in osteogenic medium on cell culture plate, hBM-
SCs-OS was relatively high on day 3, reaching the highest 
level on day 7 (680.54 ± 30.94, P < 0.01) and became stable 
afterward, expressing lower levels on days 14, 21, and 28 
(Fig. 6).
The highest level of activity among groups was found 
on day 7 in a group of hBMSCs in osteogenic medium and 
on day 14 in hESC-MSCs in osteogenic medium on collagen 
porous scaffolds. At each experimental time point, levels of 
ALP activity from hESC-MSCs in osteogenic medium on cell 
culture plates were signifi cantly higher than hESC-MSCs 
in MSC medium and lower than hESC-MSCs in osteogenic 
medium on collagen scaffolds and hBMSCs in osteogenic 
medium on cell culture plate (P < 0.01) (Fig. 6).
Osteocalcin secretion in culture medium
Levels of osteocalcin secretion from hESC-MSCs in oste-
ogenic medium on collagen scaffolds was consistently high 
(41.96 ± 3.54) and signifi cantly higher than hESC-MSCs in 
osteogenic medium on cell culture plates throughout the 
cell culture period (P < 0.05). Levels of osteocalcin secre-
tion from hESC-MSCs in osteogenic medium on cell culture 
plates were signifi cantly increased on day 28 (29.45 ± 1.19, 
P < 0.01) (Fig. 7).
Levels of calcium content in the ECM
Differentiation of hESC-MSCs in osteogenic medium into 
mature osteoblasts was further supported by mineraliza-
tion of the ECM (Fig. 7). Levels of calcium deposition per 
osteoblast-associated genes, Runx2, ALP, collagen type 
I, and bone sialoprotein. Expressions of Oct4 and Nanog 
genes were found in undifferentiated hESCs at passage 58, 
but were not expressed in the cells differentiated in osteo-
genic medium (Fig. 5). hESC-MSCs exposed to osteogenic 
medium for the fourth time (OS4) cultivated on cell culture 
plates (hESC-MSCs-OS) and on collagen scaffolds (hESC-
MSCs-OS-Scf) on culture-day 14 and the transplanted cells 
derived from FCM sorted-ALP expressing cells (ALP-FCM) 
expressed Runx2, ALP, and collagen type I similar to BMSCs 
in osteogenic medium (BMSCs-OS). Only hESC-MSCs-OS-
Scf and BMSCs-OS expressed bone sialoprotein at culture-
day 14 (Fig. 5).
Osteogenic differentiation of hESC-MSCs is 
promoted by a three-dimensional collagen matrix
During cell culture in osteogenic medium, all groups 
demonstrated similar patterns of ALP activity (Fig. 6). ALP 
activity gradually increased to reach the highest levels then 
decreased and remained stable during the later stages of 
culture. A spontaneous osteogenic differentiation of hESC-
MSCs in MSC medium was suggested by the expression of 
ALP activity reaching the highest level on day 14 (24.95 ± 
4.00, P < 0.01). ALP activity of hESC-MSCs in osteogenic 
medium on cell culture plate, hESC-MSCs-OS reached the 
highest levels on day 21 (219.01 ± 10.00, P < 0.01) and was 
stabilized by day 28. In a group of hESC-MSCs in osteogenic 
medium on collagen porous scaffolds, hESC-MSCs-OS-Scf, 
the activity was highest on day 14 (755.32 ± 83.65, P < 0.01) 
then decreased signifi cantly at day 28 (P < 0.05). The  activity 
CD29
96.54±3.22 99.40±0.22 99.06±0.16 98.06±0.48 86.42±1.30 98.37±0.22 99.42±0.22
CD44 CD49e CD73 CD90 CD105 CD166
99.85 99.20 98.59 99.83 99.33 99.42 96.13
99.43±0.51 99.70±0.24 99.67±0.18 98.92±0.22 99.02±0.60 99.38±0.32 98.75±0.35































FIG. 2. Surface antigen profi ling of human 
embryonic stem cell–derived mesenchymal 
stem cells (hESC-MSCs) and human bone mar-
row stromal cells (hBMSCs) in MSC and oste-
ogenic medium (OS). Cells were labeled and 
fl uorescent-activated cell sorted (FACS) with: 
(A) antibodies against the MSC surface anti-
gens that exhibited expression levels greater 
than 95%: CD29-FITC, CD44-APC, CD49e-PE, 
CD73-PE, CD90-PE-CY5TM, CD105-PE, and 
CD166-PE; (B) antibodies against surface 
antigens that either increased or decreased 
markedly in osteogenic medium: CD49a-PE, 
STRO-1-PE, and ALP-APC; and (C) hemato-
poietic stem cell surface antigens: CD34 
PE-CY5TM and CD45-FITC. Data from hESC-
MSCs and hESC-MSCs-OS were average val-
ues from two different cell strains at passage 
6 and data from hBMSC and hBMSC-OS were 
derived from analysis of cells from one cell 
strain at passage 4. The white histogram rep-
resents isotype controls and the black histo-
gram represents the conjugated antibody of 
each antigen.
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FIG. 4. Phase contrast images of functional 
differentiation of human embryonic stem cell–
derived mesenchymal stem cells (hESC-MSCs) 
in (A) adipogenic medium with Oil Red O stain-
ing on Day 14 demonstrating red lipid droplets in 
cytoplasm (20×); (B) chondrogenic medium with 
safranin O staining of the extracellular matrix 
(ECM) and cells with large nuclei in lacunae 
(arrow) on Day 21 (40×); (C) immunohistochemical 
staining showing patchy red staining of collagen 
type II (arrowheads); (D) Alkaline phosphatase 
(ALP) staining (blue staining) in hESC-MSCs in 
osteogenic medium (OS1) with neutral red coun-
ter stain on Day 14; (E) alizarin red staining of 
mineralized ECM on Day 21 (20×); (F) negative 
control with omission of a primary antibody; (G) 
Progression of ALP activity of hESC-MSCs in MSC 
medium, hESC-MSCs, and hESC-MSCs in osteo-
genic medium, hESC-MSCs-OS1, for a period of 28 
days. The symbol (*) represents the highest level of 
ALP activity in comparison within and between 





FIG. 3. Immunohistochemical staining of surface antigens on human embryonic stem cell–derived mesenchymal stem 
cells (hESC-MSCs) cultured in MSC medium (A–J), hESC-MSCs in osteogenic medium (K), negative control (L), and human 
bone marrow stromal cells (hBMSCs) in MSC medium (M–P). Positive staining is indicated by red-brown cytoplasmic 
staining in all images except nuclear staining of brachyury (C) and Runx2 (K). (A) hESC-MSCs-CD105, (B) CD166, (C) 
brachyury, (D) smooth muscle α-actin, (E) collagen type I, (F) vimentin, (G) VCAM-1, (H) α-fetoprotein, (I) estrogen recep-
tor α (ERα), and (J) β-catenin. (K) hESC-MSCs in osteogenic medium-Runx2. (L) Negative control omitting monoclonal 
antibody. (M) hBMSC-MSCs-CD105, (N) CD166, (O) ERα, and (P) β-catenin. (AEC substrate and hematoxylin counter stain, 
magnifi cation 20×.)
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milligram protein in a group of hESC-MSCs in osteogenic 
medium on cell culture plates were signifi cantly increased 
from day 7 to day 14 and from day 14 to day 21 (P < 0.01) and 
stabilized on day 28 (131.98 ± 3.93) (Fig. 8).
Noncollagenous bone matrix formation
von Kossa and immunohistochemical staining of bone 
matrices of hESC-MSCs on porous collagen scaffolds in 
osteogenic medium demonstrated mineralization and depo-
sition of noncollagenous matrix, ALP, osteonectin, osteopon-
tin, and osteocalcin on the peripheral area of the scaffold, 
where cells grew densely and formed a multilayer cell lin-
ing. Accumulation of cells and matrixes on the outer area 
of the scaffolds indicated uneven distribution of cell growth 
within the structure of the scaffolds (Fig. 9).
hESC-MSCs are capable of regenerating 
bone in calvarial defects
The transplanted cells were derived from the FCM-
sorted hESC-MSCs in osteogenic medium expressing ALP 
with and without GFP expression. The FCM analysis dem-
onstrated high levels of expression of the MSC cell surface 
markers, CD49a (91.7%), CD90 (94.4%), and CD105 (96.2%), 
with low expression level of STRO-1 (<0.5%). Expression of 
ALP in this population was 48.0%, and 20% of ALP-positive 
cells expressed GFP (Fig. 10A, B). The sorted cells were sub-
sequently expanded in osteogenic medium for 5 days after 
cell sorting before they were transplanted into the calvarial 
defects in nude/SCID mice.
Histologic analysis demonstrated the formation of mul-
tiple nodules of new bone in the area near to and on the 
margin of the defects. Bone marrow formation was found 
within the unorganized matrix of some bone nodules. The 
central area of defects was fi lled with loose fi brous tissue 
and vascular infi ltration. Resorption of the Bio-Oss particles 
and remnants of the Bio-Gide membrane were not observed. 
No evidence of teratoma formation was found in any of the 



















FIG. 5. Gene transcription analysis comparing expression 
of pluripotent regulator genes, Oct4 and Nanog and the 
osteoblast-associated genes, Runx2, alkaline phosphatase 
(ALP), collagen type I (ColI), and bone sialoprotein (BSP) in 
undifferentiated hESCs at passage 58 (lane 1, BGO1), FCM-
sorted ALP expressing cells (lane 2, ALP-FCM), hESC-MSCs 
in osteogenic medium (lane 3, hESC-MSCs-OS), on three-
dimensional collagen scaffolds (lane 4, hESC-MSCs-OS-
Scf), and BMSCs in osteogenic medium (lane 5, BMSCs-OS) 
on culture-day 14. BMSCs-OS served as positive control and 
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FIG. 6. Alkaline phosphatase (ALP) activ-
ity in cultured cells. Human embryonic 
stem cell–derived mesenchymal stem cells 
(hESC-MSCs) in MSC medium (hESC-MSCs-
MSC); hESC-MSCs in osteogenic medium 
(hESC-MSCs-OS); hESC-MSCs in osteogenic 
medium on collagen scaffolds (hESC-MSCs-
OS-Scf); and human bone marrow stromal 
cells (hBMSCs) in osteogenic medium (hBM-
SCs-OS), for a period of 28 days. The sym-
bol (*) represents signifi cant changes in ALP 
activity of hESC-MSCs (P < 0.01), (**) hESC-
MSCs-OS (P < 0.01), (+) hESC-MSCs-OS-Scf 
(P < 0.05), and (++) hBMSCs-OS (P < 0.01). 
n = 5, mean ± SEM.
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are present at different stages of differentiation at the time 
of harvest [27].
The current study demonstrated alternative cell culture 
conditions to a previous study [12] by reporting that the dif-
ferentiation of hESCs aggregates into multipotential MSCs 
did not require formation of embryonic body intermediates. 
Here, we did not introduce the hESCs to osteogenic medium 
at the EB stage, rather, the implanted cells were enriched 
osteoprogenitor cells derived from serial expansion of aggre-
gates of hESCs in culture medium supplemented with FBS 
[6–9,11]. We then further cultured the hESC-MSCs in oste-
ogenic medium and transplanted a FAC-sorted population 
in vivo.
Serial passaging of hESC-MSCs and hESC-MSCs-OS in 
specialized culture medium every 4–5 days restricted dif-
ferentiation of cells into specifi c lineages and generated 
large numbers of homogenous osteoprogenitor cells for 
cell stocks and transplantation [10,12], which are signifi cant 
advantages over continuous cell culture. This is because 
serial passaging of cells allows the expansion of cells at an 
early stage of differentiation [10]. In addition, passaging the 
differentiated cells at a preconfl uence stage helped to main-
tain cells in a proliferative stage for transplantation. When 
cells are allowed to differentiate for a period of time without 
subculture, the proliferating potential of cells is inhibited by 
intercellular contact and osteogenic differentiation of cells 
would advance into mature differentiation stage as dem-
onstrated by expressions profi le of ALP, osteocalcin, and 
calcium contents (Figs. 6–8). Furthermore, fully confl uent 
cells are more diffi cult to dissociate for cell transplantation 
and mature cells have a diminished capacity to differenti-
ate in vivo, leading to apoptosis of transplanted cells and a 
decrease of osteoprogenitor cells being able to sequentially 
differentiate into functional osteoblasts [28,29].
The current study supports previous studies that follow-
ing an expansion period of fi ve to six passages, hESC-derived 
MSCs exhibited the uniform fi broblast-like morphology, 
expressed high levels of MSC cell surface antigens, such 
as CD29, CD44, CD49a, CD49e, CD73, CD90, CD105, and 
Human cells were identifi ed in the newly 
formed bone
To determine the role of transplanted human cells in the 
bone regeneration process, expression of human-specifi c 
nuclear antigen and GFP expressed by the transplanted cells 
was investigated. The localization of specifi c human nuclear 
antigen in osteocytes within the new bone demonstrated cells 
of human origin (Fig. 10D). Likewise, the red-brown stain-
ing of AEC substrate on GFP antigen–streptavidin complexes 
(Fig. 10F) on osteocytes in the newly formed bone provided 
evidence of human cells participating in the regeneration of 
bone. Host calvarial bone (Fig. 10G), mouse femur (Fig. 10H), 
and a negative control that consisted of the omission of pri-
mary antibodies (Fig. 10I, J) did not demonstrate positive 
staining.
Discussion
This study describes the derivation and characterization 
of MSCs from hESC aggregates by serial passaging the dif-
ferentiated cells in culture medium supplemented with FBS 
to direct the differentiation along the mesenchymal lineage. 
We also further characterized and compared osteoblastic 
differentiation of hESC-MSCs to hBMSCs, studied the effects 
of a three-dimensional matrix on osteogenic differentiation, 
and investigated the bone regeneration capacity of the dif-
ferentiated cells in a skeletal defect.
The derivation of MSCs from hESCs for tissue regenera-
tion is a promising alternative to the use of adult stem cells. 
The potential for self-renewal and multilineage differentia-
tion distinguish hESCs from adult stem cells. Human ESCs 
represent an unlimited source of genetically identical pro-
genitor cells that creates the opportunity to manipulate the 
early stages of MSC differentiation [5,14,24]. In contrast, the 
numbers of adult stem cells in the bone marrow and adi-
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FIG. 7. Levels of osteocalcin secretion in cultured cells. 
Human embryonic stem cell–derived mesenchymal stem 
cells (hESC-MSCs) in osteogenic medium (OS) on cell cul-
ture plates and on collagen scaffolds (Scf) for 28 days. The 
symbol (*) represents a signifi cant increase in osteocalcin 
secretion from Days 7 and 14 to Day 28 (P < 0.05) and (+) sig-
nifi cant higher levels of osteocalcin in hESC-MSCs-OS-Scf 































7 d 14 d
*
21 d 28 d
FIG. 8. Calcium content in the extracellular matrix (ECM) 
of human embryonic stem cell–derived mesenchymal stem 
cells (hESC-MSCs) in osteogenic medium on cell culture 
plates for a culture period for 28 days. The symbol (*) rep-
resents signifi cant difference from Days 7 and 21 and 28 
(P < 0.01) (n = 4, mean ± SEM).
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FIG. 9. von Kossa and immunohistochemical staining of paraffi n-embedded sections of human embryonic stem cell–
derived mesenchymal stem cells (hESC-MSCs) in osteogenic medium on collagen scaffold for 28 days demonstrating min-
eralization of the extracellular matrix (A) and deposition of noncollagenous bone matrix on the scaffold (B–E) (20X). (A) von 
Kossa staining (black stain) and immunohistochemical staining of noncollagenous matrix proteins (B) ALP, (C) osteonectin, 
(D) osteopontin, and (E) osteocalcin secreted by cells on the scaffold. (F) Negative control with omission of primary antibod-
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FIG. 10. Intramembranous bone for-
mation in calvarial defects by the trans-
planted osteoblast-like cells derived from 
human embryonic stem cell–derived 
mesenchymal stem cells (hESC-MSCs) 
cultured in osteogenic medium. (A) FAC 
sorting of APC-conjugated alkaline phos-
phatase (ALP) and green fl uorescent 
protein (GFP) of cells before transplan-
tation (Gate R2). (B) ALP staining of the 
sorted ALP-positive cells (blue) counter-
stained with neutral red (red) (20×). (C,E) 
Histological images of newly formed 
bone (NB) near the margins of the defect 
(H&E, 40×). (D) Staining of human-spe-
cifi c nuclear antigen (HuNu) and (F) GFP 
staining of osteocytes in new bone matrix 
(arrow). (G) Negative staining of HuNu 
mAb on the mature host bone. (H) HuNu 
staining of mouse femur. (I) Negative 
control of HuNu and (J) GFP staining 
with omission of primary antibodies. 
Magnifi cation of images C–F was 40× 
and G–J was 20×.
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dimensional collagen scaffolds and fi brin gel support cell 
growth and promote osteoblastic differentiation of human 
MSCs and osteoblast-like cells in osteogenic medium [50,51]. 
This is likely due to the promotion of cell–cell and cell–ECM 
interactions in the three-dimensional matrix that are crucial 
for effi cient growth and differentiation [52–54].
The current study also demonstrates the bone formation 
capacity of the enriched osteoprogenitor cell population 
derived from hES cells in the calvarial defect model (Fig. 10) 
and emphasizes the importance of delivering lineage-spe-
cifi c cells into such a skeletal defect to ensure formation of 
a predetermined tissue type and avoid spontaneous differ-
entiation into undesired lineages [14]. The osteoprogenitor 
cell population in the differentiated hESC-MSCs in osteo-
genic medium was enriched by selective cell sorting using 
expression of ALP as a cell surface marker (Fig. 10A, B). The 
advantage of ALP selective cell sorting is to enrich the num-
bers of ALP-positive colonies [55] and to obtain an enriched 
population of preosteoblasts in the late proliferation stage 
(STRO-1−/ALP+) [33]. However, it is possible that ALP 
sorted cells may be contaminated with pluripotent cells, as 
ALP is expressed in undifferentiated hESCs [6], and is also 
expressed in cultured preosteoblastic and osteogenic cells 
[33,55]. To determine the presence of undifferentiated hESCs 
or pluripotent cells in the osteogenically differentiated cells, 
RT-PCR was performed to compare expression of key regu-
lators of pluripotency, Oct4 and Nanog genes [56] and the 
osteoblast-related genes, Runx2, collagen type I, and bone 
sialoprotein [33,57] in undifferentiated hESCs, differentiated 
hESC-MSCs in osteogenic medium, and the enriched popu-
lation of ALP expressing cells for transplantation (Fig. 5).
The gene expression profi les of Oct4 and Nanog, Runx2, 
collagen type I, and bone sialoprotein demonstrate that the 
cells in osteogenic medium (hESC-MSCs-Os) differentiated 
into osteoblasts and lost their self-renewal capability, as there 
was no expression of Oct4 and Nanog in the differentiated 
cells and the ALP-enriched population, but expression of 
osteoblasts-related genes was enhanced [33,57] (Fig. 5). This 
conclusion is also supported by the lack of teratoma forma-
tion in the transplanted site up to 6 weeks in vivo (Fig. 10). 
Taken together, the data demonstrate that there was no con-
tamination of undifferentiated hESCs in the population of 
osteogenically differentiated hESC-MSCs.
The fate of transplanted cells in the bone formation process 
was verifi ed by identifying the presence of human cells in 
the matrix of the newly formed bone. Immunohistochemical 
staining of a specifi c nuclear antigen and identifi cation of 
transfected GFP protein ensured identifi cation of human 
cells functioning in the defect site (Fig. 10D,F) [58]. These 
data support previous reports that hESCs exposed to an 
osteogenic induction environment in vitro were able to form 
bone in ectopic sites [8,9,20,28] and emphasize that the differ-
entiated cells were lineage-specifi c and able to form bone in 
the calvarial defect (Fig. 10).
In the current study, transplanted cells did not regenerate 
enough bone to bridge the critical size cranial defect. Based 
on studies of bone formation capacity of hBMSCs, this limita-
tion may be related to poor survival of cells after transplan-
tation that was compromised by local environmental factors 
such as hypoxia and delayed angiogenesis [59] and ability of 
the cell delivery vehicle to support osteogenic differentiation 
[60,61]. Uneven distribution of Bio-Oss particles in the defect 
site and their small particle size (0.25–1.0 mm) might also 
CD166, and did not express the hematopoietic lineage mark-
ers, CD34 and CD45 (Fig. 2) [10,12,30]. These fi ndings are 
consistent with the observed phenotype of MSCs from bone 
marrow (BMSCs) [31,32] and hESCs-derived MSCs [12,16,30] 
with slight differences in the degree of expression (Fig. 2).
Expression of the STRO-1 antigen, which is expressed on 
multipotential BMSC progenitor cells, was clearly detected 
in hESC-MSCs at levels comparable to BMSCs [33] (Fig. 2B). 
Furthermore, intense staining suggesting high expression 
levels of estrogen receptor-α (ER-α) and β-catenin on hESC-
MSCs and hBMSCs found in the current study (Fig. 3I,J and 
O,P) strengthen the similarity of phenotypes between hESC-
MSCs and BMSCs and suggests potential roles of estrogen 
and Wnt signaling in controlling osteogenic differentia-
tion of hESC-MSCs [34–36]. Additionally, the homogenous 
fi broblast-like cell morphology (Fig. 1C) [12,30], expression 
of proteins associating with mesenchyme, such as α-smooth 
muscle actin, collagen type I, and vimentin [37], and a lack 
of α-fetoprotein expression (Fig. 3C–H) indicate that in the 
described culture conditions, hESCs differentiated specifi -
cally into cells of the mesenchymal lineage [3,32].
Increasing levels of ALP and low level of STRO-1 expres-
sions of cells in osteogenic medium (Fig. 2B) indicated an 
early stage of osteoblastic differentiation [33]. The continual 
high expression of all MSCs surface markers on the differen-
tiated cells in osteogenic medium (Fig. 2A) is consistent with 
the observations of MSC cell surface antigens on osteoblasts 
in various differentiation stages suggesting their association 
with proliferation and differentiation of cells [38–40]. The 
expression of CD49a (α1 integrin) may promote osteogenic 
differentiation of hESC-MSCs in osteogenic medium, as it 
was markedly increased in the differentiated cells (Fig. 2B) 
and found strongly expressed on osteoblasts [41]. Only hBM-
SCs expressing CD49a have been shown to form multipoten-
tial colony forming unit-fi broblasts (CFU-Fs) in vitro [42,43]. 
Taken together, the fi ndings support a model in which cell 
surface antigens of MSCs are not specifi cally expressed on 
MSCs [32] and advocate their roles on regulating growth 
and osteogenic differentiation [38–40,44,45].
Expression of brachyury (Fig. 3C) in hESC-MSCs cultured 
in MSC medium and Runx2 in hESC-MSCs cultured in oste-
ogenic medium (Fig. 3K) suggest that hESCs differentiated 
to MSCs and subsequently differentiated into osteoblastic 
cells [6,33,46]. The sequential pattern of differentiation of 
hESC-MSCs into mature osteoblasts (Figs. 6–8) was similar 
to the temporal pattern observed in hBMSCs and primary 
osteoblasts [33,47,48]. Human ESCs-MSCs-OS demonstrated 
the progression of osteoblastic differentiation into three 
temporal phases: proliferation, matrix maturation, and min-
eralization phases [38,49], as indicated by the temporal pat-
tern of expressions of ALP activity, levels of osteocalcin and 
calcium content in ECM (Figs. 6–8).
The differentiated hESC-MSCs exhibited the phenotypes 
of mature osteoblasts by producing osteocalcin and deposit-
ing calcium within the ECM [47,49] (Figs. 6–8). The cells also 
secreted noncollagenous bone proteins such as osteonectin, 
osteopontin, and osteocalcin when grown on the porous 
collagen scaffolds (Fig. 9). Furthermore, the fi ndings that 
only hESC-MSCs-OS on collagen scaffold expressed BSP 
(Fig. 5) and levels of ALP activity and osteocalcin secretion 
on the three-dimensional matrix were signifi cantly higher 
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